# Vincent Miles

> Vincent Miles is a Series B investor at Abingworth backing Biotechnology. See 7 investments, check sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [Abingworth](https://shizune.co/investors/profile/abingworth-management)
- Location: Boston, United States
- Total investments: 7
- Last investment: Feb 2015
- Lead investor: 29%
- Last updated: Oct 2026
- Website: https://www.vjmiles.com

Vincent Miles is a Series B investor at Abingworth in Boston focused on Biotechnology and Biopharma. Vincent J. Miles is based out of Boston, Massachusetts and is the Executive Director of Abingworth. Vincent previously worked at Alnylam Pharmaceuticals as a Senior Vice President, Business Development. Vincent J. Miles attended the University College London.

## Contacts

5 contacts available for Vincent Miles: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/vincent-miles?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Biopharma | 2 | 29% |
| Medical | 1 | 14% |
| Chemical | 1 | 14% |
| Genetics | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 29% |
| Series C | 2 | 29% |
| Series D | 2 | 29% |
| Series E | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $70M | Series E | Feb 27, 2015 | https://chiasma.com |
| Chiasma | Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $38.5M | Series D | Jul 23, 2012 | https://chiasma.com |
| PrimeraDx (Primera Biosystems) | PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; andFungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts. | $20M | Series C | Oct 30, 2009 | http://www.primeradx.com |
| Hydra Biosciences | Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $22M | Series D | Jan 16, 2009 | http://www.hydrabiosciences.com |
| Hydra Biosciences | Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $34M | Series C | Mar 13, 2008 | http://www.hydrabiosciences.com |
| PrimeraDx (Primera Biosystems) | PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; andFungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts. | $21M | Series B | Jan 09, 2008 | http://www.primeradx.com |
| Hydra Biosciences | Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that addresssignificant unmet medical needs.Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures. | $18.9M | Series B | Jan 12, 2004 | http://www.hydrabiosciences.com |

7 of 7 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 4 deals together
- [Lilly Ventures](https://shizune.co/investors/profile/lilly-ventures) — VC Fund, 3 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 3 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 2 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Bioventures Investors](https://shizune.co/investors/profile/bioventures-investors) — VC Fund, 2 deals together

## About Abingworth

VC Fund · London, United Kingdom

Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciencessectors.Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park, and Boston, Abingworth has invested in 142 life science companies, completed 60 IPOs and 40 mergers and acquisitions.

5 contacts available at Abingworth.

| Name | Title | Profile |
| --- | --- | --- |
| Brian Gallagher | Partner | https://shizune.co/investors/profile/brian-gallagher |
| Quentin Lloyd-Harris | Partner | https://shizune.co/investors/profile/genghis-lloyd-harris |
| Vincent Miles | Partner | https://shizune.co/investors/profile/vincent-miles |
| Alex Asquith | General Counsel and Chief Financial Officer | https://shizune.co/investors/profile/alex-asquith |
| Andrew Sinclair | Partner & Portfolio Manager | https://shizune.co/investors/profile/andrew-sinclair |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Vincent Miles invest in?

Vincent Miles invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Vincent Miles?

Public channels for Vincent Miles include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Vincent Miles last invest?

The most recent investment recorded for Vincent Miles closed in Feb 2015. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co